The DOI matches its Crossref record; 216 of the 216 references it cites were found in a registry or an index.
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., Hall, S. D., et al. (2001) · Nature Genetics · doi:10.1038/86882 · Cited by 2,162
Ingelman-Sundberg, M., Sim, S. C., Gomez, A., & Rodriguez-Antona, C. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.09.004 · Cited by 1,166
Ingelman-Sundberg, M. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500285 · Cited by 1,108
Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism
Desta, Z., Zhao, X., Shin, J.-G., & Flockhart, D. A. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241120-00002 · Cited by 942
Hulot, J.-S. (2006) · Blood · doi:10.1182/blood-2006-04-013052 · Cited by 931
Predicting in vivo drug interactions from in vitro drug discovery data
Wienkers, L. C., & Heath, T. G. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1851 · Cited by 904
Pharmacokinetics of selective serotonin reuptake inhibitors
Hiemke, C., & Härtter, S. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00048-0 · Cited by 883
Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
NEUVONEN, P., NIEMI, M., & BACKMAN, J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.003 · Cited by 859
Human P450 metabolism of warfarin
Kaminsky, L. S., & Zhang, Z.-Y. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(96)00140-4 · Cited by 798
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry
Zanger, U. M., Raimundo, S., & Eichelbaum, M. (2004) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-003-0832-2 · Cited by 795
Self-citationSachse, C., Brockmöller, J., Bauer, S., & Roots, I. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00898.x · Cited by 751
BRANDT, J. T., CLOSE, S. L., ITURRIA, S. J., PAYNE, C. D., FARID, N. A., ERNEST, C. S., LACHNO, D. R., SALAZAR, D., & WINTERS, K. J. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02775.x · Cited by 734
SIM, S., RISINGER, C., DAHL, M., AKLILLU, E., CHRISTENSEN, M., BERTILSSON, L., & INGELMANSUNDBERG, M. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.10.002 · Cited by 732
Kirchheiner, J., Nickchen, K., Bauer, M., Wong, M.-L., Licinio, J., Roots, I., & Brockmöller, J. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001494 · Cited by 724
Pharmacogenomics and Individualized Drug Therapy
Eichelbaum, M., Ingelman-Sundberg, M., & Evans, W. E. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104724 · Cited by 720
Codeine Intoxication Associated with Ultrarapid CYP2D6 Metabolism
Gasche, Y., Daali, Y., Fathi, M., Chiappe, A., Cottini, S., Dayer, P., & Desmeules, J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041888 · Cited by 702
Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data
Lee, C. R., Goldstein, J. A., & Pieper, J. A. (2002) · Pharmacogenetics · doi:10.1097/00008571-200204000-00010 · Cited by 686
Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother
Koren, G., Cairns, J., Chitayat, D., Gaedigk, A., & Leeder, S. J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69255-6 · Cited by 684
The genetic determinants of the CYP3A5 polymorphism
Hustert, E., Haberl, M., Burk, O., Wolbold, R., He, Y.-Q., Klein, K., Nuessler, A. C., Neuhaus, P., Klattig, J., Eiselt, R., et al. (2001) · Pharmacogenetics · doi:10.1097/00008571-200112000-00005 · Cited by 673
Self-citationHesselink, D. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00168-1 · Cited by 655
Circadian Rhythms: Mechanisms and Therapeutic Implications
Levi, F., & Schibler, U. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105208 · Cited by 645
Johansson, I., Lundqvist, E., Bertilsson, L., Dahl, M. L., Sjöqvist, F., & Ingelman-Sundberg, M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11825 · Cited by 644
Butler, M. A., Iwasaki, M., Guengerich, F. P., & Kadlubar, F. F. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.20.7696 · Cited by 638
Clinical relevance of genetic polymorphisms in the human CYP2C subfamily
Goldstein, J. A. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01499.x · Cited by 617
Lang, T., Klein, K., Fischer, J., Nussler, A. K., Neuhaus, P., Hofmann, U., Eichelbaum, M., Schwab, M. G., & Zanger, U. M. (2001) · Pharmacogenetics · doi:10.1097/00008571-200107000-00004 · Cited by 574
Self-citationSex Is A Major Determinant of Cyp3a4 Expression in Human Liver
Wolbold, R., Klein, K., Burk, O., Nüssler, A. K., Neuhaus, P., Eichelbaum, M., Schwab, M., & Zanger, U. M. (2003) · Hepatology · doi:10.1002/hep.1840380424 · Cited by 529
Self-citationDai, D., Zeldin, D. C., Blaisdell, J. A., Chanas, B., Coulter, S. J., Ghanayem, B. I., & Goldstein, J. A. (2001) · Pharmacogenetics · doi:10.1097/00008571-200110000-00006 · Cited by 494
BORGES, S., DESTA, Z., LI, L., SKAAR, T., WARD, B., NGUYEN, A., JIN, Y., STORNIOLO, A., NIKOLOFF, D., & WU, L. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.03.013 · Cited by 487
Clinical consequences of cytochrome P450 2C9 polymorphisms
KIRCHHEINER, J., & BROCKMOLLER, J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.08.009 · Cited by 474
Schroth, W., Antoniadou, L., Fritz, P., Schwab, M., Muerdter, T., Zanger, U. M., Simon, W., Eichelbaum, M., & Brauch, H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2705 · Cited by 467
Self-citationAmirimani, B., Walker, A. H., Weber, B. L., & Rebbeck, T. R. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.18.1588 · Cited by 465
Growth Hormone Regulation of Sex-Dependent Liver Gene Expression
Waxman, D. J., & O’Connor, C. (2006) · Molecular Endocrinology · doi:10.1210/me.2006-0007 · Cited by 458
Johnson, M. D., Zuo, H., Lee, K.-H., Trebley, J. P., Rae, J. M., Weatherman, R. V., Desta, Z., Flockhart, D. A., & Skaar, T. C. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000025406.31193.e8 · Cited by 456
REGULATION OF DRUG-METABOLIZING ENZYMES AND TRANSPORTERS IN INFLAMMATION
Aitken, A. E., Richardson, T. A., & Morgan, E. T. (2006) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141059 · Cited by 448
Özdemir, V., KALOW, W., Tang, B.-K., Paterson, A. D., Walker, S. E., Endrényi, L., & Kashuba, A. D. M. (2000) · Pharmacogenetics · doi:10.1097/00008571-200007000-00001 · Cited by 440
Kirchheiner, J., Schmidt, H., Tzvetkov, M., Keulen, J.-T., Lötsch, J., Roots, I., & Brockmöller, J. (2007) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500406 · Cited by 439
Human liver carbamazepine metabolism
Kerr, B. M., Thummel, K. E., Wurden, C. J., Klein, S. M., Kroetz, D. L., Gonzalez, F. J., & Levy, R. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90071-x · Cited by 433
Pharmacogenetics – five decades of therapeutic lessons from genetic diversity
Meyer, U. A. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1428 · Cited by 420
LALOVIC, B., KHARASCH, E., HOFFER, C., RISLER, L., LIUCHEN, L., & SHEN, D. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.01.009 · Cited by 413
MicroRNA Regulates the Expression of Human Cytochrome P450 1B1
Tsuchiya, Y., Nakajima, M., Takagi, S., Taniya, T., & Yokoi, T. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1403 · Cited by 408
Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice
Gardiner, S. J., & Begg, E. J. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.6 · Cited by 406
Hesse, L. M., Venkatakrishnan, K., Court, M. H., von Moltke, L. L., Duan, S. X., Shader, R. I., & Greenblatt, D. J. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12046-9 · Cited by 397
Schwab, M., Zanger, U. M., Marx, C., Schaeffeler, E., Klein, K., Dippon, J., Kerb, R., Blievernicht, J., Fischer, J., Hofmann, U., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4182 · Cited by 393
Self-citationClinical Pharmacokinetics of Quetiapine: An Atypical Antipsychotic
DeVane, C. L., & Nemeroff, C. B. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140070-00003 · Cited by 386
Clarke, T. A., & Waskell, L. A. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.1.53 · Cited by 374
Modification of Clinical Presentation of Prostate Tumors by a Novel Genetic Variant in CYP3A4
Rebbeck, T. R., Jaffe, J. M., Walker, A. H., Wein, A. J., & Malkowicz, S. B. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.16.1225 · Cited by 360
Faucette, S. R., Hawke, R. L., Lecluyse, E. L., Shord, S. S., Yan, B., Laethem, R. M., & Lindley, C. M. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12054-8 · Cited by 353
Nakajima, M., Yokoi, T., Mizutani, M., Kinoshitah, M., Funayama, M., & Kamataki, T. (1999) · Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a022352 · Cited by 346
Gemfibrozil greatly increases plasma concentrations of cerivastatin
Backman, J. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.128469 · Cited by 336
Buprenorphine: Clinical Pharmacokinetics in the Treatment of Opioid Dependence
Elkader, A., & Sproule, B. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544070-00001 · Cited by 335
Pascussi, J. M., Gerbal-Chaloin, S., Drocourt, L., Maurel, P., & Vilarem, M. J. (2003) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(02)00483-x · Cited by 330
Ogilvie, B. W., Zhang, D., Li, W., Rodrigues, A. D., Gipson, A. E., Holsapple, J., Toren, P., & Parkinson, A. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.007633 · Cited by 330
Clinical Pharmacokinetics of Mirtazapine
Timmer, C. J., Ad Sitsen, J. M., & Delbressine, L. P. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038060-00001 · Cited by 319
Abram, S. E. (2007) · Yearbook of Anesthesiology and Pain Management · doi:10.1016/s1073-5437(08)70202-x · Cited by 318
Identification of an inducible form of cytochrome P-450 in human liver.
Watkins, P. B., Wrighton, S. A., Maurel, P., Schuetz, E. G., Mendez-Picon, G., Parker, G. A., & Guzelian, P. S. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.18.6310 · Cited by 317
Association of CYP 3 A 4 genotype with treatment-related leukemia
Felix, C. A., Walker, A. H., Lange, B. J., Williams, T. M., Winick, N. J., Cheung, N.-K. V., Lovett, B. D., Nowell, P. C., Blair, I. A., & Rebbeck, T. R. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13176 · Cited by 310
Yamazaki, H., & Shimada, T. (1997) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1997.0302 · Cited by 310
Westlind, A., Löfberg, L., Tindberg, N., Andersson, T. B., & Ingelman-Sundberg, M. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0752 · Cited by 300
The Influence of Age and Sex on the Clearance of Cytochrome P450 3A Substrates
Cotreau, M. M., von Moltke, L. L., & Greenblatt, D. J. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544010-00002 · Cited by 292
Savi, P., Combalbert, J., Gaich, C., Rouchon, M.-C., Maffrand, J., Berger, Y., & Herbert, J. (1994) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1648859 · Cited by 283
57 Varieties: The Human Cytochromes P450
Lewis, D. F. (2004) · Pharmacogenomics · doi:10.1517/phgs.5.3.305.29827 · Cited by 277
Stereoselective Metabolism of Omeprazole by Human Cytochrome P450 Enzymes
Äbelö, A., Andersson, T. B., Antonsson, M., Naudot, A. K., Skånberg, I., & Weidolf, L. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15171-9 · Cited by 276
Klein, K., Lang, T., Saussele, T., Barbosa-Sicard, E., Schunck, W.-H., Eichelbaum, M., Schwab, M., & Zanger, U. M. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01213011-200512000-00004 · Cited by 269
Self-citationLeemann, T., Transon, C., & Dayer, P. (1993) · Life Sciences · doi:10.1016/0024-3205(93)90285-b · Cited by 267
Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6
Zanger, U. M., Fischer, J., Raimundo, S., Stüven, T., Evert, B. O., Schwab, M., & Eichelbaum, M. (2001) · Pharmacogenetics · doi:10.1097/00008571-200110000-00004 · Cited by 266
Self-citationGhotbi, R., Christensen, M., Roh, H.-K., Ingelman-Sundberg, M., Aklillu, E., & Bertilsson, L. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0288-2 · Cited by 264
CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates
Takanashi, K., Tainaka, H., Kobayashi, K., Yasumori, T., Hosakawa, M., & Chiba, K. (2000) · Pharmacogenetics · doi:10.1097/00008571-200003000-00001 · Cited by 261
Clinical Pharmacokinetics of Fibric Acid Derivatives (Fibrates)
Miller, D. B., & Spence, J. D. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199834020-00003 · Cited by 259
Polymorphic CYP2B6: Molecular Mechanisms and Emerging Clinical Significance
Zanger, U. M., Klein, K., Saussele, T., Blievernicht, J., H Hofmann, M., & Schwab, M. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.7.743 · Cited by 258
Self-citationRotger, M., Tegude, H., Colombo, S., Cavassini, M., Furrer, H., Décosterd, L., Blievernicht, J., Saussele, T., Günthard, H. F., Schwab, M., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100072 · Cited by 257
Self-citationClinical Pharmacokinetic Profile of Modafinil
Robertson, P., & Hellriegel, E. T. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342020-00002 · Cited by 256
Eap, C. B., Crettol, S., Rougier, J.-S., Schläpfer, J., Sintra Grilo, L., Déglon, J.-J., Besson, J., Croquette-Krokar, M., Carrupt, P.-A., & Abriel, H. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100120 · Cited by 255
Furuta, T. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113959 · Cited by 254
Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6
Kirchheiner, J., Klein, C., Meineke, I., Sasse, J., Zanger, U. M., M??rdter, T. E., Roots, I., & Brockm??ller, J. (2003) · Pharmacogenetics · doi:10.1097/00008571-200310000-00005 · Cited by 249
Self-citationCYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine
Shams, M. E. E., Arneth, B., Hiemke, C., Dragicevic, A., Muller, M. J., Kaiser, R., Lackner, K., & Hartter, S. (2006) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2006.00763.x · Cited by 246
Rasmussen (2002) · Pharmacogenetics · doi:10.1097/00008571-200208000-00008 · Cited by 241
Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone
Baldwin, Clarke, & Chenery (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00030.x · Cited by 235
Bahadur, N., Leathart, J. B. S., Mutch, E., Steimel-Crespi, D., Dunn, S. A., Gilissen, R., Houdt, J. V., Hendrickx, J., Mannens, G., Bohets, H., et al. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01354-0 · Cited by 235
Rudberg, I., Mohebi, B., Hermann, M., Refsum, H., & Molden, E. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100291 · Cited by 232
Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C
Hamman, M. A., Thompson, G. A., & Hall, S. D. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00143-3 · Cited by 230
Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment
CRETTOL, S., DEGLON, J., BESSON, J., CROQUETTEKROKKAR, M., GOTHUEY, I., HAMMIG, R., MONNAT, M., HUTTEMANN, H., BAUMANN, P., & EAP, C. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.08.011 · Cited by 228
Stereoselective metabolism of methadone N‐demethylation by cytochrome P4502B6 and 2C19
Gerber, J. G., Rhodes, R. J., & Gal, J. (2004) · Chirality · doi:10.1002/chir.10303 · Cited by 228
Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin
Flockhart, D. A., O'Kane, D., Williams, M. S., Watson, M. S., Flockhart, D. A., Gage, B., Gandolfi, R., King, R., Lyon, E., Nussbaum, R., et al. (2008) · Genetics in Medicine · doi:10.1097/gim.0b013e318163c35f · Cited by 227
Andersson, T., Miners, J., Veronese, M., & Birkett, D. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04336.x · Cited by 225
Paracetamol, alcohol and the liver
Prescott, L. F. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00167.x · Cited by 223
Gatanaga, H., Hayashida, T., Tsuchiya, K., Yoshino, M., Kuwahara, T., Tsukada, H., Fujimoto, K., Sato, I., Ueda, M., Horiba, M., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/522175 · Cited by 223
Impact of CYP2B6 Polymorphism on Hepatic Efavirenz Metabolism in Vitro
Desta, Z., Saussele, T., Ward, B., Blievernicht, J., Li, L., Klein, K., Flockhart, D. A., & Zanger, U. M. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.6.547 · Cited by 222
Self-citationJover, R., Bort, R., Gómez‐Lechón, M. J., & Castell, J. V. (2002) · The FASEB Journal · doi:10.1096/fj.02-0195fje · Cited by 221
Ring, B. J., Catlow, J., Lindsay, T. J., Gillespie, T., Roskos, L. K., Cerimele, B. J., Swanson, S. P., Hamman, M. A., & Wrighton, S. A. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12326-4 · Cited by 214
Gonzalez, F. J. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.012492 · Cited by 213
Frere, C., Cuisset, T., Morange, P.-E., Quilici, J., Camoin-Jau, L., Saut, N., Faille, D., Lambert, M., Juhan-Vague, I., Bonnet, J.-L., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.11.065 · Cited by 210
Hofmann, M. H., Blievernicht, J. K., Klein, K., Saussele, T., Schaeffeler, E., Schwab, M., & Zanger, U. M. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.133306 · Cited by 210
Self-citationStearns, R. A., Chakravarty, P. K., Chen, R., & Chiu, S. H. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06520-1 · Cited by 208
Identification of P450 enzymes involved in metabolism of verapamil in humans
Kroemer, H., Gautier, J.-C., Beaune, P., Henderson, C., Roland Wolf, C., & Eichelbaum, M. (1993) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/bf00169164 · Cited by 200
Ferguson, S. S., Chen, Y., LeCluyse, E. L., Negishi, M., & Goldstein, J. A. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.013169 · Cited by 200
Drugs as CYP3A Probes, Inducers, and Inhibitors
Liu, Y.-T., Hao, H.-P., Liu, C.-X., Wang, G.-J., & Xie, H.-G. (2007) · Drug Metabolism Reviews · doi:10.1080/03602530701690374 · Cited by 196
Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug Response
Goetz, M. P., Kamal, A., & Ames, M. M. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100367 · Cited by 193
Role of CYP2B6 in Stereoselective Human Methadone Metabolism
Totah, R. A., Sheffels, P., Roberts, T., Whittington, D., Thummel, K., & Kharasch, E. D. (2008) · Anesthesiology · doi:10.1097/aln.0b013e3181642938 · Cited by 192
Subrahmanyam, V. V., Renwick, A. B., Walters, D. G., Young, P. J., Price, R. J., Tonelli, A. P., & Lake, B. G. (2001) · PubMed · Cited by 190
Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4.
Feierman, D. E., & Lasker, J. M. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07486-0 · Cited by 189
Henningsson, A., Marsh, S., Loos, W. J., Karlsson, M. O., Garsa, A., Mross, K., Mielke, S., Viganò, L., Locatelli, A., Verweij, J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1152 · Cited by 188
CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver.
Dehal, S. S., & Kupfer, D. (1997) · PubMed · Cited by 187
Molecular Mechanisms of Polymorphic CYP3A7 Expression in Adult Human Liver and Intestine
Burk, O., Tegude, H., Koch, I., Hustert, E., Wolbold, R., Glaeser, H., Klein, K., Fromm, M. F., Nuessler, A. K., Neuhaus, P., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202345200 · Cited by 185
Self-citationIncreased transcriptional activity of the CYP3A4*1B promoter variant
Amirimani, B., Ning, B., Deitz, A. C., Weber, B. L., Kadlubar, F. F., & Rebbeck, T. R. (2003) · Environmental and Molecular Mutagenesis · doi:10.1002/em.10199 · Cited by 182
Cytochrome P450s and cholesterol homeostasis
Pikuleva, I. A. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.05.014 · Cited by 182
GARCIAMARTIN, E. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.04.006 · Cited by 182
Steimer, W., Zöpf, K., von Amelunxen, S., Pfeiffer, H., Bachofer, J., Popp, J., Messner, B., Kissling, W., & Leucht, S. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2004.041327 · Cited by 181
Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide
Niemi, M. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00228-5 · Cited by 181
Pilotto, A., Seripa, D., Franceschi, M., Scarcelli, C., Colaizzo, D., Grandone, E., Niro, V., Andriulli, A., Leandro, G., di Mario, F., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.025 · Cited by 177
van der Weide, J., Steijns, L. S., & van Weelden, M. J. (2003) · Pharmacogenetics · doi:10.1097/00008571-200303000-00006 · Cited by 176
Parikh, S., Ouedraogo, J.-B., Goldstein, J. A., Rosenthal, P. J., & Kroetz, D. L. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100122 · Cited by 172
Cribb, A. E., Spielberg, S. P., & Griffin, G. P. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06552-3 · Cited by 169
Cytochrome P450 3A and their regulation
Burk, O., & Wojnowski, L. (2004) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-003-0815-3 · Cited by 168
Ohyama, K., Nakajima, M., Nakamura, S., Shimada, N., Yamazaki, H., & Yokoi, T. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15077-5 · Cited by 166
RAIMUNDO, S. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.04.009 · Cited by 163
Otton, S. V., Crewe, H. K., Lennard, M. S., Tucker, G. T., & Woods, H. F. (1988) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20010-6 · Cited by 162
Kiang, T. K. L., Ho, P. C., Anari, M. R., Tong, V., Abbott, F. S., & Chang, T. K. H. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfl096 · Cited by 160
Tang, C., Shou, M., Mei, Q., Rushmore, T. H., & Rodrigues, A. D. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39255-9 · Cited by 159
Regulating the regulator: Factors that control levels and activity of the aryl hydrocarbon receptor
Harper, P. A., Riddick, D. S., & Okey, A. B. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.01.007 · Cited by 159
Ferguson, S. S., LeCluyse, E. L., Negishi, M., & Goldstein, J. A. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.3.737 · Cited by 158
Interethnic and Intraethnic Variability of CYP2C8 and CYP2C9 Polymorphisms in Healthy Individuals
García‐Martín, E., Martínez, C., Ladero, J. M., & Agúndez, J. A. G. (2006) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256440 · Cited by 157
Determinants of the rate of nicotine metabolism and effects on smoking behavior
Johnstone, E. C., BENOWITZ, N., Cargill, A., JACOB, R., Hinks, L. J., Day, I. N. M., MURPHY, M., & Walton, R. T. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.06.011 · Cited by 156
Holstein, A., Plaschke, A., Ptak, M., Egberts, E. ‐., El-Din, J. S., Brockmöller, J., & Kirchheiner, J. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02379.x · Cited by 155
Sibutramine: A Serotonin–Norepinephrine Reuptake-Inhibitor for the Treatment of Obesity
Luque, C. A., & Rey, J. A. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.18319 · Cited by 155
CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-rime PCR
Schaeffeler, E., Schwab, M. G., Eichelbaum, M. F., & Zanger, U. M. (2003) · Human Mutation · doi:10.1002/humu.10280 · Cited by 153
Self-citationOldham, H. G., & Clarke, S. E. (1997) · PubMed · Cited by 150
Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole*
Kivistö, K. T., Lamberg, T. S., Kantola, T., & Neuvonen, P. J. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90038-2 · Cited by 147
Jaakkola, T., Laitila, J., Neuvonen, P. J., & Backman, J. T. (2006) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2006.pto_437.x · Cited by 145
Hutchinson, M. R., Menelaou, A., Foster, D. J. R., Coller, J. K., & Somogyi, A. A. (2004) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.02002.x · Cited by 144
Differential expression and function of CYP2C isoforms in human intestine and liver
pple, F. L., von Richter, O., Fromm, M. F., Richter, T., Thon, K. P., Wisser, H., Griese, E., Eichelbaum, M. F., & Kivist, K. T. (2003) · Pharmacogenetics · doi:10.1097/00008571-200309000-00005 · Cited by 144
Lc, M., & Daly, A. K. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00356-7 · Cited by 143
Warrington, J. S., Shader, R. I., Moltke, L. L., & Greenblatt, D. J. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15055-6 · Cited by 139
Ad, R., Roberts, E. M., Dj, M., Yao, Y., & Ouellet, D. (1997) · PubMed · Cited by 139
Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19
Hoffman, S. M. G., Nelson, D. R., & Keeney, D. S. (2001) · Pharmacogenetics · doi:10.1097/00008571-200111000-00007 · Cited by 138
Lamba, J. K., Lamba, V., Strom, S. C., Venkataramanan, R., & Schuetz, E. G. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.016600 · Cited by 136
Metabolism of Meloxicam in human liver involves cytochromes P4502C9 and 3A4
Chesné, C., Guyomard, C., Guillouzo, A., SCHMID, J., Ludwig, E., & SAUTER, T. (1998) · Xenobiotica · doi:10.1080/004982598239704 · Cited by 134
Identification of the Human Cytochromes P450 Responsible for Atomoxetine Metabolism
Ring, B. J., Gillespie, J. S., Eckstein, J. A., & Wrighton, S. A. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.3.319 · Cited by 133
Nakajima, M., Komagata, S., Fujiki, Y., KANADA, Y., Ebi, H., Itoh, K., Mukai, H., Yokoi, T., & Minami, H. (2007) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328045c4fb · Cited by 133
Klotz, U. E. (2006) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp44297 · Cited by 132
Prakash, C., Kamel, A. M., Cui, D., Whalen, R., Miceli, J. J., & Tweedie, D. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00151.x · Cited by 131
Genetic Variability in CYP2A6 and the Pharmacokinetics of Nicotine
Mwenifumbo, J. C., & Tyndale, R. F. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.10.1385 · Cited by 131
Impact of genotype on adverse effects during treatment with metoprolol: A prospective clinical study
Fux, R., Mörike, K., Pröhmer, A. M. T., Delabar, U., Schwab, M. G., Schaeffeler, E., LORENZ, G., Gleiter, C. H., Eichelbaum, M. F., & Kivistö, K. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.07.004 · Cited by 126
Self-citationPharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype
Kirchheiner, J., THOMAS, S., Bauer, S., Tomalik‐Scharte, D., Hering, U., Doroshyenko, O., Jetter, A., Stehle, S., Tsahuridu, M., & Meineke, I. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.008 · Cited by 126
Stürmer, E., Moltke, L. L., Shader, R. I., & Greenblatt, D. J. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12045-7 · Cited by 126
Penzak, S., Kabuye, G., Mugyenyi, P. N., Mbamanya, F., Natarajan, V., Alfaro, R., Kityo, C. M., Formentini, E., & Masur, H. (2007) · HIV Medicine · doi:10.1111/j.1468-1293.2007.00432.x · Cited by 120
A COMBINED APPROACH TO DRUG METABOLISM AND TOXICITY ASSESSMENT
Ekins, S., Andreyev, S., Ryabov, A., Kirillov, E., Rakhmatulin, E. A., Sorokina, S. Y., Bugrim, A. E., & Nikolskaya, T. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.008458 · Cited by 117
Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources.
Rotzinger, S., Fang, J., & Baker, G. B. (1998) · PubMed · Cited by 116
Benedetti, M. S., Plisnier, M., Kaise, J., Maier, L., Baltes, E., Arendt, C. H., & McCracken, N. W. (2001) · European Journal of Clinical Pharmacology · doi:10.1007/s002280100364 · Cited by 116
Structures of cytochrome P450 3A4
Scott, E. E., & Halpert, J. R. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2004.11.004 · Cited by 114
IN VITRO METABOLISM OF CLINDAMYCIN IN HUMAN LIVER AND INTESTINAL MICROSOMES
Wynalda, M. A., Hutzler, J. M., Koets, M. D., Podoll, T., & Wienkers, L. C. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.7.878 · Cited by 114
Desta, Z., Wu, G. M., Morocho, A. M., & Flockhart, D. A. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.3.336 · Cited by 113
Rochat, B., Amey, M., Gillet, M., Meyer, U., & Baumann, P. (1997) · Pharmacogenetics · doi:10.1097/00008571-199702000-00001 · Cited by 111
Najib, J. S. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.04.014 · Cited by 110
Oxidative metabolism of zolpidem by human liver cytochrome P450S.
Pichard‐Garcia, L., Gillet, G., Bonfils, C., Domergue, J., Thénot, J., & Maurel, P. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06824-2 · Cited by 108
Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation
David, S. P., Brown, R. A., Papandonatos, G. D., Kahler, C. W., Lloyd‐Richardson, E. E., Munafo, M. R., Shields, P. G., Lerman, C. E., Strong, D. R., McCaffery, J. M., et al. (2007) · Nicotine & Tobacco Research · doi:10.1080/14622200701382033 · Cited by 107
Yumibe, N. P., Huie, K., Chen, K.-J., Snow, M. E., Clement, R. P., & Cayen, M. N. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)02169-8 · Cited by 106
Busse, D., Cosme, J., Beaune, P. H., Kroemer, H., Eichelbaum, M. F., Busse, D., Kroemer, H. K., & Eichelbaum, M. F. (1995) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00168924 · Cited by 105
MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype
Lamba, J. K., Strom, S. C., VENKATARAMANAN, R., Thummel, K. E., LIN, Y., LIU, W., Cheng, C. Y., Lamba, V., Watkins, P. B., & Schuetz, E. G. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.11.013 · Cited by 105
Padol, S., Yuan, Y., Thabane, M. E., Padol, I. T., & Hunt, R. H. (2007) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp45188 · Cited by 105
Pharmacogenetics of cyclophosphamide in patients with hematological malignancies
Xie, H., Griškevičius, L., Ståhle, L., Hassan, Z., Yaşar, Ü., Rane, A., Broberg, U., Kimby, E. K., & Hassan, M. (2005) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2005.08.008 · Cited by 103
Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro
Granfors, M. T., Backman, J. T., Laitila, J., & Neuvonen, P. J. (2004) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.02028.x · Cited by 98
THE INVOLVEMENT OF CYP3A4 AND CYP2C9 IN THE METABOLISM OF 17α-ETHINYLESTRADIOL
Wang, B., Sánchez, R. I., Franklin, R. B., Evans, D. C., & Huskey, S.-E. W. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000182 · Cited by 98
Schwab, M. G., Schaeffeler, E., Klotz, U. E., & Treiber, G. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.05.002 · Cited by 97
Self-citationSearch for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype
Jiang, Z., Dragin, N., Jorge-Nebert, L. F., Martin, M. V., Guengerich, F. P., Aklillu, E., Ingelman‐Sundberg, M., Hammons, G., Lyn‐Cook, B. D., Kadlubar, F. F., et al. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000204994.99429.46 · Cited by 93
Cytochrome P4503APolymorphisms and Immunosuppressive Drugs: An Update
Anglicheau, D., Legendre, C. M., Beaune, P. H., & Thervet, É. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.7.835 · Cited by 93
Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2
Han, X., Ouyang, D., Chen, X., Shu, Y., Jiang, C., Tan, Z., & Zhou, H. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01686.x · Cited by 92
Effect of tadalafil on cytochrome P450 3A4?mediated clearance: Studies in vitro and in vivo
Ring, B. J., Patterson, B. E., MITCHELL, M., VandenBranden, M. R., Gillespie, J. S., Bedding, A. W., Jewell, H., PAYNE, C., Forgue, S. T., Eckstein, J. A., et al. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.09.006 · Cited by 92
Some Aspects of Genetic Polymorphism in the Biotransformation of Antidepressants
Brøsen, K. (2004) · Therapies · doi:10.2515/therapie:2004003 · Cited by 92
Nielsen, K. K., Brøsen, K., Hansen, M. G. J., & Gram, L. F. (1994) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1994.65 · Cited by 91
Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor
VandenBranden, M. R., Ring, B. J., Binkley, S. N., et al. (1996) · Pharmacogenetics · doi:10.1097/00008571-199602000-00007 · Cited by 90
In Vitro and In Vivo Evaluations of Cytochrome P450 1A2 Interactions with Duloxetine
Lobo, E. D., Bergstrom, R. F., Reddy, S. R., Quinlan, T., Chappell, J., Hong, Q., Ring, B. J., & Knadler, M. P. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847030-00005 · Cited by 89
Applications of AmpliChip??? CYP450
Jain, K. K. (2005) · Molecular Diagnosis · doi:10.2165/00066982-200509030-00002 · Cited by 88
Bertilsson, L. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100358 · Cited by 88
Toscano, C., Klein, K., Blievernicht, J., Schaeffeler, E., Saußele, T., Raimundo, S., Eichelbaum, M. F., Schwab, M. G., & Zanger, U. M. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000230112.96086.e0 · Cited by 85
Self-citationHuman cytochrome P450s involved in the metabolism of 9-cis- and 13-cis-retinoic acids
Marill, J., Capron, C., Idres, N., & Chabot, G. G. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00925-x · Cited by 81
Mehlotra, R. K., Bockarie, M. J., & Zimmerman, P. A. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02884.x · Cited by 74
Bach, M., Coutts, R. T., & Baker, G. B. (1999) · Xenobiotica · doi:10.1080/004982599238344 · Cited by 73
Functional characterization of four allelic variants of human cytochrome P450 1A2
Zhou, H., Josephy, P. D., Kim, D., & Guengerich, F. P. (2003) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2003.11.019 · Cited by 73
Selective Induction of Human Hepatic Cytochromes P450 2B6 and 3A4 by Metamizole
Saußele, T., Burk, O., Blievernicht, J. K., Klein, K., Nussler, A. K., Nüssler, N. C., Hengstler, J. G., Eichelbaum, M. F., Schwab, M. G., & Zanger, U. M. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100138 · Cited by 72
Self-citationCytochromes P450 mediating the N‐demethylation of amitriptyline
Ghahramani, P., Ellis, S. W., Lennard, M. S., Ramsay, L. E., & Tucker, G. T. (1997) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1997.05382.x · Cited by 71
Sex-Dependent Genetic Markers of CYP3A4 Expression and Activity in Human Liver Microsomes
Schirmer, M., Rosenberger, A., Klein, K., Kulle, B., Toliat, M. R., Nürnberg, P., Zanger, U. M., & Wojnowski, L. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.5.443 · Cited by 70
Self-citationPharmacogenetics of Anti-HIV Drugs
Telenti, A., & Zanger, U. M. (2007) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094753 · Cited by 70
Self-citationRole of Cytochrome P-4502C9 in Irbesartan Oxidation by Human Liver Microsomes
Bourrié, M., Meunier, V., Berger, Y., et al. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15292-0 · Cited by 69
Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation
Tracy, T. S., Marra, C., Wrighton, S. A., et al. (1997) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050293 · Cited by 67
Long, J., Egan, K. M., Dunning, L., Shu, X., Cai, Q., Cai, H., Dai, Q., Holtzman, J. L., Gao, Y.-T., & Zheng, W. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000189803.34339.ed · Cited by 66
Tiseo, Perdomo, & Friedhoff (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.0460s1030.x · Cited by 66
Tomlinson, E. S., Lewis, D. F. V., Maggs, J. L., Kroemer, H. K., Park, B. K., & Back, D. J. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00166-4 · Cited by 64
Role of human cytochrome P450 3A4 in metabolism of medroxyprogesterone acetate.
Kobayashi, K., Mimura, N., Fujii, H., Minami, H., Sasaki, Y., Shimada, N., & Chiba, K. (2000) · PubMed · Cited by 64
Tanaka, Μ. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113723 · Cited by 63
The G−113A polymorphism in affects the caffeine metabolic ratio in a Chinese population
Chen, X., WANG, L., ZHI, L., Zhou, G.-D., WANG, H., ZHANG, X., Hao, B., Zhu, Y., Cheng, Z., & HE, F. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.05.012 · Cited by 63
CYP3A5 Genotype has an Impact on the Metabolism of the HIV Protease Inhibitor Saquinavir
Josephson, F., Allqvist, A., Janabi, M., Sayi, J., Aklillu, E., Jande, M. B., Mahindi, M., Burhenne, J., Böttiger, Y., Gustafsson, L. L., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100117 · Cited by 63
Relative Contribution of CYP3A to Amitriptyline Clearance in Humans: In Vitro and In Vivo Studies
Venkatakrishnan, K., Schmider, J., Harmatz, J. S., Ehrenberg, B. L., Moltke, L. L., Graf, J. A., Mertzanis, P., Corbett, K. E., Rodriguez, M. C., Shader, R. I., et al. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122012634 · Cited by 63
CYP2C8 and antimalaria drug efficacy
Gil, J., & Berglund, E. G. (2007) · Pharmacogenomics (London) · doi:10.2217/14622416.8.2.187 · Cited by 61
Schwab, M. G., Klotz, U. E., Hofmann, U., Schaeffeler, E., LEODOLTER, A., Malfertheiner, P., & Treiber, G. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.08.017 · Cited by 57
Self-citationUnraveling gene-gene interactions regulated by ligands of the aryl hydrocarbon receptor
Johnson, C. D., Balagurunathan, Y., Tadesse, M. G., Falahatpisheh, M. H., Brun, M., Walker, M. K., Dougherty, E. R., & Ramos, K. S. (2004) · Environmental Health Perspectives · doi:10.1289/ehp.6758 · Cited by 55
BIOTRANSFORMATION OF FLUTICASONE: IN VITRO CHARACTERIZATION
Pearce, R. E., Leeder, J. S., & Kearns, G. L. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.009043 · Cited by 55
Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations
Schirmer, M., Toliat, M. R., Haberl, M., Suk, A., Kamdem, L. K., Klein, K., Brockmöller, J., Nürnberg, P., Zanger, U. M., & Wojnowski, L. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000182779.03180.ba · Cited by 50
Self-citationLöfgren, S., Baldwin, R. M., Hiratsuka, M., Lindqvist, A., Carlberg, A., Sim, S. C., Schuelke, M., Snait, M., Edenro, A., Fransson-Steen, R., et al. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.019349 · Cited by 50
Pharmacokinetics of Duloxetine in Breast Milk and Plasma of Healthy Postpartum Women
Lobo, E. D., Loghin, C., Knadler, M. P., Quinlan, T., Zhang, L., Chappell, J., Lucas, R., & Bergstrom, R. F. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847020-00003 · Cited by 49
Formation of meprobamate from carisoprodol is catalysed byCYP2C19
Dal??n, P., Alván, G., Wakelkamp, M., et al. (1996) · Pharmacogenetics · doi:10.1097/00008571-199610000-00002 · Cited by 45
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
“The cytochromes P450 (CYPs) constitute the major enzyme family capable of catalyzing the oxidative biotransformation of most drugs and other lipophilic xenobiotics and are therefore of particular relevance for clinical pharmacology (Nelson, 2004; Guengerich, 2008; Zanger et al., 2008).”
BackgroundSelf-citationCollet, J.-P., Hulot, J.-S., Pena, A., Villard, E., Esteve, J.-B., Silvain, J., Payot, L., Brugier, D., Cayla, G., Beygui, F., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61845-0 · Cited by 967
Alternative (non-animal) methods for cosmetics testing: current status and future prospects—2010
Adler, S., Basketter, D., Creton, S., Pelkonen, O., van Benthem, J., Zuang, V., Andersen, K. E., Angers-Loustau, A., Aptula, A., Bal-Price, A., et al. (2011) · Archives of Toxicology · doi:10.1007/s00204-011-0693-2 · Cited by 584
Parolini, M. (2020) · Science of The Total Environment · doi:10.1016/j.scitotenv.2020.140043 · Cited by 420
The Curious Case of the HepG2 Cell Line: 40 Years of Expertise
Arzumanian, V. A., Kiseleva, O. I., & Poverennaya, E. V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313135 · Cited by 387
Metadata
- Authors
- Zanger, U. M., Turpeinen, M., Klein, K., & Schwab, M.
- Venue
- Analytical and Bioanalytical Chemistry
- Published
- 2008-08-10
- Volume
- 392
- Issue
- 6
- Pages
- 1093-1108
- ISSN
- 1618-2642 (ISSN-L)
- 1618-2650
- OpenAlex
- W2068780263
- Cited by
- 593
- References
- 216
- FWCI
- 34.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.